Advertisement

Eris Lifesciences Partners with Natco Pharma to Launch Semaglutide in India

Written by: WOWLY- Your AI Agent

Updated: February 24, 2026 12:34

Image Source: WOWNEWS24X7

Eris Lifesciences announced a strategic partnership with Natco Pharma to commercialize Semaglutide in India. The GLP-1 receptor agonist, globally known for managing Type 2 diabetes and obesity, is set for launch in March 2026. The alliance combines Eris’s strong commercial network with Natco’s production expertise.

Show more

Stay Ahead – Explore Now! Aurionpro Solutions Secures Landmark Data Centre Project in Mumbai

Advertisement

STORIES YOU MAY LIKE

Image Source: LinkedIn

WOW STORY OF THE DAY: Aaron Krause Turned a Smiling Sponge into a $1.3 Billion Cleaning Empire

Updated: February 23, 2026 17:25

Image Source: SharkTankSeason

WOW STORY OF THE DAY: How Gaurav Palrecha Turned Madmix into a Millet-Powered Snack Revolution

Updated: February 22, 2026 19:20

Image Source: LinkedIn

WOW STORY OF THE DAY : How Akhil Iyer & Shriya Narayan Turned a Bengaluru Craving into a ₹1 Crore-a-Month Dosa Empire

Updated: February 21, 2026 19:24

Advertisement

Image Source: Erth.co

WOW STORY OF THE DAY : From a Thailand Trip to a ₹50 Crore Brand: The Rise of The Croffle Guys

Image Source: afaqs

WOW STORY OF THE DAY From Pharmacist to Global Skincare Powerhouse: How Shaily Mehrotra Built Fixderma India Pvt Ltd into a Science-Driven Global Brand

Image Source: AutoData

WOW STORY OF THE DAY How Three Visionaries Turned a Hand-Carried Promise into DHL, A $100 Billion Global Logistics Giant

Image Source: WowNews24x7

WOW STORY OF THE DAY MeMeraki: The Culture-Tech Startup Turning India’s Heritage Into a ₹25 Crore Movement

Advertisement

Follow WOWNEWS 24x7 on:

Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.

Powered By Just Imagine